Healthcare101

 The mRNA synthesis and manufacturing market is projected to reach USD 2.96 billion by 2029 from USD 2.23 billion in 2024, at a CAGR of 5.8% from 2024 to 2029. The market growth is fueled by rising demand in clinical trials for mRNA vaccines, along with the increased outsourcing of mRNA synthesis and production. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=105705347 Browse in-depth TOC on “mRNA Synthesis & Manufacturing Market” 250 — Tables 50 — Figures 250 — Pages KEY TAKEAWAYS The North America mRNA synthesis & manufacturing market accounted for a 47.1% revenue share in 2024. By product, the instruments segment is expected to register the highest CAGR of 5.8% By service, the mRNA synthesis & modification services segment is expected to register the highest CAGR of 7.6% By application, the cell & gene therapies segment is projected to grow at the fastest rate from 2024 to 2029. By end user (product), the pharmaceutical & biotec...

 The global Injectable Drug Delivery Market , valued at US$633.7 billion in 2024, is forecasted to grow at a robust CAGR of 8.4%, reaching US$690.23 billion in 2025 and an impressive US$1,034.78 billion by 2030. The injectable drug delivery market is driven by the rising prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, alongside an increasing global demand for biologics. Developed markets like the US, Germany, and Japan continue to adopt advanced delivery technologies, supported by strong healthcare infrastructure and patient preference for convenient, self-administered therapies. In emerging markets such as India, Brazil, and China, market growth is accelerated by improved healthcare access and government-backed immunization and chronic disease management programs. Key market trends include the increasing adoption of wearable injectors, autoinjectors, and needle-free systems. This shift is largely driven by a growing emphasis on patient complianc...

 The global Sleep Apnea Devices Market , valued at US$6.4 billion in 2024 stood at US$6.9 billion in 2025 and is projected to advance at a resilient CAGR of 7.6% from 2025 to 2032, culminating in a forecasted valuation of US$11.6 billion by the end of the period. The sleep apnea devices market is experiencing significant growth, primarily driven by the increasing integration of telemedicine, mobile health (mHealth), and artificial intelligence in the diagnostic and therapeutic processes for sleep apnea. The expansion of key market players into emerging economies like India, Australia, the UAE, and Saudi Arabia is further enhancing this market’s potential. Additionally, there is a notable trend among health agencies to expand reimbursement policies for remote patient monitoring and related connected healthcare services, which is improving accessibility to advanced sleep apnea management solutions. Furthermore, innovative developments such as compact positive airway pressure (PAP) de...

 The global Single-use Bioprocessing Market , valued at US$16.51 billion in 2024, stood at US$18.01 billion in 2025 and is projected to advance at a resilient CAGR of 13.3% from 2025 to 2030, culminating in a forecasted valuation of US$33.67 billion by the end of the period. Some factors contributing to the growth of the global single-use bioprocessing market include the growing adoption among contract development & manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs), the increased productivity, and the reduced risk of cross-contamination. Moreover, reduced capital investment and the thriving biologics & biosimilar markets bolster the market growth. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297 Browse in-depth TOC on “ Single Use Bioprocessing Market “ 740 — Tables 65 — Figures 570 — Pages Based on region , the single-use bioprocessing market is segmented into six major regions, namely North Americ...

 The global cell therapy technologies market , valued at US$3.89 billion in 2023 , stood at US$4.03 billion in 2024 and is projected to advance at a robust CAGR of 11.0% from 2024 to 2029 , reaching a forecasted valuation of US$6.80 billion by the end of the period. This growth underscores the transformative potential of cell therapy technologies in modern healthcare, driven by advancements in regenerative medicine , increasing R&D investments , and the rising prevalence of chronic and rare diseases worldwide. Emerging trends such as the integration of artificial intelligence (AI) and machine learning (ML) into cell therapy workflows are revolutionizing the industry by optimizing production processes, enhancing precision, and improving therapeutic outcomes. Moreover, the shift toward allogeneic cell therapies , offering scalability and wider accessibility, is further propelling market expansion. The rise of cell and gene therapy hubs across North America, Europe, and Asi...

 The global biopharmaceutical contract manufacturing market , valued at US$20.51 billion in 2024 , stood at US$22.40 billion in 2025 and is projected to grow at a CAGR of 8.8% from 2025 to 2030, reaching a forecasted US$34.15 billion by 2030 . This robust growth reflects the rising global demand for outsourcing services, fueled by increasing biologics and biosimilars production, as well as the expanding prevalence of chronic and rare diseases. However, the market faces certain barriers related to intellectual property (IP) rights and compliance with stringent regulatory frameworks. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163964739 Attractive Opportunities in the Biopharmaceutical Contract Manufacturing Market The biopharmaceutical contract manufacturing market presents strong opportunities across multiple regions, with Asia Pacific emerging as a particularly attractive hub. The growth of the Asia Pacific market is driven by: ...